Symposium ArticleInterspecies Scaling of Regional Drug Delivery
References and Notes (31)
- et al.
J. Ped. Surg.
(1966) - et al.
Brain. Res.
(1979) - et al.
J. Pharm. Sci.
(1982) - et al.
J. Pharmacokinet. Biopharm.
(1974) - et al.
Cancer Treat. Rep.
(1977) - et al.
Cancer Treat. Rep.
(1980) - et al.
Cancer Treat. Rep.
(1984) - et al.
Cancer Treat. Rep.
(1978)
Am. Soc. Artificial Internal Organs J.
Am. J. Physiol.
Cancer Treat. Rep.
J. Cancer Treat. Rep.
J. Neuro-Oncol.
Cited by (78)
Intrathecal drug delivery in the era of nanomedicine
2020, Advanced Drug Delivery ReviewsCitation Excerpt :The nasal mucosa, especially, is an important route of clearance in small animals, whereas higher order species do not experience such high clearance through mucosal routes. Cortical folding – and thus cortical surface area – is also much higher in humans, which is an additional consideration for species scaling of IT drug delivery that has not yet been directly experimentally addressed [51]. In addition to lymphatic cranial CSF outflow via dural or cribriform lymphatics, spinal CSF outflow has also been observed in preventrebral lymph nodes under conditions of high volume, high pressure intrathecal or intracisternal fluid injections [43,52].
Subarachnoid Hemorrhage
2018, Handbook of Neuroemergency Clinical Trials: Second EditionSubarachnoid Hemorrhage
2017, Handbook of Neuroemergency Clinical TrialsVaginal drug distribution modeling
2015, Advanced Drug Delivery ReviewsIntraperitoneal chemotherapy for peritoneal surface malignancy: Experience with 1,000 patients
2014, Journal of the American College of SurgeonsCitation Excerpt :Any systemic chemotherapy for intraperitoneal disease must overcome the plasma-peritoneal partition to reach molecular targets. Pharmacokinetic studies have confirmed the presence of this peritoneal-plasma partition by demonstrating that drugs delivered into the peritoneal cavity have a clearance that is inversely proportional to the square root of its molecular weight.31-33 Delivery of intraperitoneal chemotherapy can be viewed as a tool to overcome this drug resistance, as well the toxicity attendant to systemic administration.
A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C
2013, Journal of Surgical ResearchCitation Excerpt :Early studies confirmed the presence of a peritoneal–plasma partition by demonstrating that drugs delivered into the peritoneal cavity have a clearance that is inversely proportional to the square root of its molecular weight owing to this partition. Drugs without lipophilic properties and high molecular weights have optimal pharmacokinetic profiles for intraperitoneal application [4–6]. Mitomycin C (MMC), an alkylating agent, is presently the most commonly used chemotherapeutic agent for hyperthermic intraperitoneal treatment [7].